Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142584 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension
A Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 336
- Enrollment target
NCT00142584: Completed Phase 3 study, sponsored by Mylan Bertek Pharmaceuticals.
NCT00142584 is a Phase 3 study that has completed, run by Mylan Bertek Pharmaceuticals. The registered enrollment target is 336 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00142584, a Phase 3 study, has completed, sponsored by Mylan Bertek Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 336 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate long-term safety,tolerability and blood pressure effects of metoprolol versus nebivolol in patients with hypertension. These drugs may be given alone or in combination with other drugs that are commonly used in the treatment of hypertension
Primary Outcome
The primary efficacy parameter was the change in the average trough sitting DBP at the end of treatment (Visit 10 or Early Termination) compared with baseline (baseline was defined as the baseline visit in Study NEB 310 \[NCT00145210\]).
Interventions
- DRUG Nebivolol (NEB)
- DRUG Metoprolol (MET)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 336 participants |
| Start Date | 2005-08 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
What the finished NCT00142584 record still lists
NCT00142584 is an interventional study that assigns participants to a tested intervention. The registered 336 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Nebivolol (NEB) is the first listed.
NCT00142584 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00142584 about?
NCT00142584 is a clinical study titled "Evaluation of the Long-term Safety and Tolerability of Metoprolol Versus Nebivolol in Patients With Hypertension". The purpose of this study is to evaluate long-term safety,tolerability and blood pressure effects of metoprolol versus nebivolol in patients with hypertension. These drugs may be given alone or in combination with other drugs that are commonly used in the treatment of hypertension
What is the current status of trial NCT00142584?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 336 participants. The study started on 2005-08. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00142584?
The interventions under investigation include: Nebivolol (NEB) (DRUG), Metoprolol (MET) (DRUG).
Who is sponsoring clinical trial NCT00142584?
This trial is sponsored by Mylan Bertek Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00142584's enrollment target sits among peer trials
336 1060th of 2000 higher than 940 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- NCT03977207 · 336 participants · NA
A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients
- NCT04665206 · 336 participants · Phase 1
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
- NCT05124457 · 336 participants · Phase 2
DETERMINE: Detemir vs NPH
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia